Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on April 29, 2013, to report a significant regulatory milestone. The Company is a biopharmaceutical firm focused on developing and commercializing plant-made biopharmaceuticals.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is the receipt of regulatory approvals for the Company's product, UPLYSO (alfataliglicerase). Specifically:
- The Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) granted approval.
- The Public Health Institute of Chile granted approval.
- These approvals cover the use of UPLYSO for long-term enzyme replacement therapy in adults with a confirmed diagnosis of Type I Gaucher disease.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) but does not include specific forward-looking guidance, financial outlook, management commentary on future performance, or a discussion of risks and contingencies within the text of the 8-K itself. No unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the commercial launch timeline and market entry strategy for UPLYSO in Mexico and Chile.
- Review the full text of the press release (Exhibit 99.1) for details on pricing, distribution agreements, or sales projections.
- Assess the impact of these approvals on the Company's overall regulatory strategy for other international markets.
- Check subsequent filings for any financial impact or revenue recognition related to these new approvals.